US Patent 7202216 Drug therapy for celiac sprue

Celiac Sprue and/or dermatitis herpetiformis are treated by interfering with HLA binding of immunogenic gluten peptides. The antigenicity of gluten oligopeptides and the ill effects caused by an immune response thereto are decreased by administration of an HLA-binding peptide inhibitor. Such inhibitors are analogs of immunogenic gluten peptides and (i) retain the to bind tightly to HLA molecules; (ii) retain the protcolytic stability of these peptides; but (iii) are unable to T cells.